]>
IRCT20200817048437N1 IRCT 2020-09-08 Esfahan University of Medical Sciences Effect of Kligman plus Methimazol in treatment of melasma Compare the effect of Kligman plus Methimazole 5% combination against Kligman alone in the treatment of melasma 2020-09-22 anticipated 44 Complete https://irct.ir/trial/50401 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: According to the table of random numbers each patient is randomly instructed to apply A cream to the left and B cream to the right of the face or vice versa, Blinding description: Each patient is given two creams with the same package shape, coded A and B.The evaluating physician and the patient are both unaware of the contents of the two creams. 3 Melasma. Intervention group: Each patient is given two creams,One of the creams contains Kligman(B) and another one contains Kligman and Methimazol(A).Each of the creams is rubbed on one side of the face(split face).. Yes - There is a plan to make this available What will be shared: Data are published that have nothing to do with the personality and identity of the participants in this study and are only the results of the study. When: The data are available six months after the publication of the article in the journal. To whom: Approved university researchers are allowed to access the data after being authenticated by the relevant university. Conditions: The data can only be used for research purposes, such as writing review articles. Where to obtain: To receive the data, the corresponding author can be accessed via the email and telephone number of the university mentioned in the article. How to obtain: After reviewing the data access request, if approved, it is for non-industrial and non-commercial uses, the data will be provided to the applicant. Comments:
public Mahsa Akhtari Boruojeni
No D-14,Toranj Apartment,Sabur Alley,Tolu Alley,West Tohid Blvd,Sepahanshahr
Isfahan Iran (Islamic Republic of) 8179981786 +98 31 3653 2286 mahsaakhtari@gmail.com Esfahan University of Medical Sciences scientific Mahsa Akhtari Boruojeni
No D-14,Toranj Apartment,Sabur Alley,Tolu Alley,West Tohid Blvd,Sepahanshahr
Isfahan Iran (Islamic Republic of) 8179981786 +98 31 3653 2286 mahsaakhtari@gmail.com Esfahan University of Medical Sciences Iran (Islamic Republic of) All patients with melasma no limit no limit Both pregnancy lactation Treatment with OCP and HRT Use of drugs that darken the color of the skin History of allergy to topical and systemic steroids and thyroid drugs in at least the last 30 days History of Severe systemic disease History of any thyroid disease L81.1 Chloasma Treatment - Drugs Intervention group: Each patient is given two creams,One of the creams contains Kligman(B) and another one contains Kligman and Methimazol(A).Each of the creams is rubbed on one side of the face(split face). The severity of melasma lesions is measured according to the The Melasma area and severity index (MASI) , which includes three factors: percentage of facial involvement, darkness and homogeneity. Timepoint: Measurement of the Melasma area and severity index (MASI score) at the beginning of the study and 8 weeks after the start of the drug intervention. Method of measurement: The Melasma area and severity index (MASI). Esfahan University of Medical Sciences Approved 2020-06-06 Ethics Committee of Isfahan University of Medical Sciences Isfahan University of Medical Sciences,Hezarjarib Ave Isfahan Isfehan Iran (Islamic Republic of)